Erenumab is a fully human monoclonal antibody. Erenumab inhibits the calcitonin gene–related peptide (CGRP) receptor. Erenumab can be used for the prevention of episodic migraine[1].
References
[1] Goadsby PJ, Reuter U, Hallstrm Y, et al. A Controlled Trial of Erenumab for Episodic Migraine.N Engl J Med. 2017;377(22):2123-2132. DOI:10.1056/NEJMoa1705848
